RELAX-AHF: Benefit of serelaxin extends across multiple subgroups

Overall, there was no difference in the effects of serelaxin vs placebo on dyspnea relief or the incidence of cardiovascular/rehospitalizations for heart failure or renal failure at 60 days, report investigators. While the results were homogenous across multiple subgroups, there were some interactions that hinted at potentially larger reductions in mortality in some patients.
Source: theHeart.org - Category: Cardiology Source Type: news